Kaken Pharmaceutical Co., Ltd.

Update in progress

4521.T (Tokyo)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Kaken Pharmaceutical Co., Ltd. develops, manufactures, and sells medical products, devices, and agrochemicals in Japan and abroad. Its portfolio includes Clenafin, Artz, Fiblast, Ecclock, Regroth, Hernicore, and Seprafilm. It markets agrochemicals and animal health products and is active in several clinical programs, including KP-001 and Seladelpar, plus early trials like Tildacerfont. It collaborates with Alumis on ESK-001 TYK2 inhibitor and rents Bunkyo Green Court. Founded 1917, Tokyo.

Company score

Sentiment: 0.26; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive